2005
DOI: 10.1159/000086780
|View full text |Cite
|
Sign up to set email alerts
|

Final Results of a Prospective Trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen Followed by Radiotherapy after Curative Surgery for Pancreatic Adenocarcinoma

Abstract: Background: Postoperative management of patients with pancreatic adenocarcinoma (PA) is controversial. Methods: The aim of this pilot study was to assess the feasibility of postoperative combination chemotherapy followed by radiotherapy in patients aged 18–70 years with a histological diagnosis of PA, and Karnofsky performance status (KPS) ≧70. Cisplatin and epirubicin 40 mg/m2 on day 1, gemcitabine 600 mg/m2 on day 1 and 8, and 5-fluorouracil 200 mg/m2/day as protracted infusi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
7
0
1

Year Published

2006
2006
2018
2018

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(8 citation statements)
references
References 54 publications
0
7
0
1
Order By: Relevance
“…6,[22][23][24][25] Briefly, dose adjustments, which were made according to the greatest degree of toxicity, consisted of reduction in gemcitabine dose by 25% in case of grade 2 neutropenia or grade 1 thrombocytopenia. Treatment was delayed for a maximum of 2 weeks in case of grade Ն3 neutropenia, anemia or nonhematological toxicity, or of grade Ͼ1 thrombocytopenia.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…6,[22][23][24][25] Briefly, dose adjustments, which were made according to the greatest degree of toxicity, consisted of reduction in gemcitabine dose by 25% in case of grade 2 neutropenia or grade 1 thrombocytopenia. Treatment was delayed for a maximum of 2 weeks in case of grade Ն3 neutropenia, anemia or nonhematological toxicity, or of grade Ͼ1 thrombocytopenia.…”
Section: Methodsmentioning
confidence: 99%
“…The present report describes a series of 46 patients with progressive or recurrent pancreatic adenocarcinoma after gemcitabine-based chemotherapy who were submitted to second-line chemotherapy with either classic PEFG regimen (until April 2004) 6,22,23 or dose-intense PEFG regimen (since May 2004). 24,25 …”
mentioning
confidence: 99%
“…Drugs such as mitomycin C (recommendation grade: A, evidence level 1) [213], a combination of cisplatin, epirubicine, 5-FU, and gemcitabine (PEFG) (recommendation grade: A, evidence level 2) [224], and a combination of gemcitabine and docetaxel (recommendation grade: B, evidence level 2b) [225 -228] are not important in first line therapy of metastatic or locally advanced, inoperable pancreatic carcinoma.…”
Section: Other Drugsmentioning
confidence: 99%
“…Substanzen wie Mitomycin C (Empfehlungsgrad: A, Evidenzstärke 1) [212], die Kombination aus Cisplatin, Epirubicin, 5-FU und Gemcitabin (PEFG) (Empfehlungsgrad: A, Evidenzstärke 2) [223] und die Kombination aus Gemcitabin und Docetaxel (Empfehlungsgrad: B, Evidenzstärke 2b) [224 -227]…”
Section: Weitere Substanzenunclassified